CovaSyn
All Articles
Position8 min readMay 21, 2026

Data quality isn't the real bottleneck. Why 55 percent of biotech AI pilots actually fail.

In the Benchling Biotech AI Report 2026, 55 percent of 100 surveyed AI leaders name "poor data quality" as the top reason their pilots fail. The industry conclusion — "we need better data management" — addresses the symptom, not the cause. A counter-thesis, three real failure modes, and a concrete proposal.

OK

Oliver Kraft

CovaSyn

Data quality isn't the real bottleneck. Why 55 percent of biotech AI pilots actually fail.

The number half the industry is currently anchored on

In May 2026, Benchling published the Biotech AI Report 2026. n=100, all AI leaders at biotech companies, honest self-assessments of "why are our pilots failing". The most-cited stat: 55 percent name poor data quality as the top reason.

The stat is correct. The obvious takeaway — "we need better data management, therefore a new data platform" — is wrong. Or at least incomplete. Anyone who adopts it without thinking buys a platform and keeps failing.

Why? Because "data quality" in pharma AI pilots means two very different things, and the industry conflates them systematically.

What "data quality" actually means — two distinct problems

When a med-chem team reports "our AI pilot failed on data quality", they usually mean one of two things:

1. Input-side data quality. Structure data in the internal ELN is inconsistent, SMILES sometimes in a special syntax, assay values without units. This is a classic data-management problem. A data platform helps here. 2. Output-side reproducibility. The agent gives different logP values for the same question in two runs, ICH M7 categorisations switch between "high concern" and "low concern", stability predictions on the third call no longer match the first. This is not a data-management problem. A better data platform doesn't fix it.

Both problems are bucketed under "poor data quality" in the Benchling survey. Anyone in a pharma org with a GxP posture knows: the second problem is what actually kills pilots. You can have the cleanest input data in the world — if your validation-relevant answer on call 1,000 looks different from call 1, the thing never moves past PoC.

The three real failure modes of biotech AI pilots

From the discovery calls we've had with failed pilots over the past twelve months, three patterns keep showing up. None of them is primarily a data problem:

1. Hallucination in the value space.

The LLM agent makes up plausible but wrong numbers. logP 2.3 instead of 4.1. Pyridine pKa "around 5" when the real answer is 5.23. In an academic setting "around" is fine. In a pharma submission setting, a logP off by 1.8 means the auditor returns the dossier. Symptom: pilots that shine in the demo and die in validation.

2. Lack of audit trail.

The agent gives an answer, three weeks later someone asks "how was this produced", and nobody can reproduce it. In an EU Annex 11 / 21 CFR Part 11 environment, a non-reproducible answer is a non-existent answer. Symptom: pilot gets removed from the QA audit loop.

3. Inconsistency between runs.

Same input, different answer. At temperature 0 an LLM should be deterministic — but it isn't necessarily, because the inference pipeline introduces floating-point variation and because many "tool calls" are actually new LLM inferences with small context shifts. Symptom: validation protocol can't be closed out.

What ties all three failure modes together: they don't sit in the input data, they sit in the inference layer. A better data platform doesn't change any of this.

Where the fix sits: deterministic tools instead of LLM inference for computation

The architecture that addresses these three failure modes isn't "more LLM" or "better prompt engineering". It's a strict separation between two layers:

  • LLM layer: generates hypotheses, suggests workflows, interprets results, talks to the user. Hallucination is tolerable here because a human is in the loop.
  • Tool layer: runs deterministic computation. logP via RDKit. ICH M7 classification via a versioned Q-SAR. Stability via Arrhenius kinetics. Hallucination is catastrophic here — so it's technically ruled out by not running the computation in the LLM, but in a plain Python function with a defined input-output contract.

Not new as an idea. New since 2024 is that there is a standard for it: the Model Context Protocol (MCP), specified by Anthropic, maintained jointly since 2025 by Anthropic, OpenAI and major open-source projects. MCP standardises the interface through which an LLM agent calls these deterministic tools.

What this looks like in numbers

We measured it on an independent benchmark — MolecularIQ from the Klambauer Lab (JKU Linz), 3,540 verified chemistry tasks, ICLR 2026. Three frontier LLMs:

  • Claude Haiku 4.5: 21.2 % accuracy without tools, 85.4 % with CovaSyn MCP. 4.0× lift.
  • Claude Opus 4.7: 40.8 % → 91.5 %. 2.3×.
  • OpenAI GPT-5.5: 22.3 % → 89.9 %. 4.0×.

The lift is not model-specific. It doesn't come from the newer model having learned more. It comes from the deterministic tool layer eliminating hallucination. Methodology and full numbers at /en/benchmark.

So if you stay with Benchling's 55 %: halving the share lets you stand out in the industry. Cutting it to a third gives you a competitive advantage the others won't catch up to in the next two years. The lever for it is the deterministic tool layer, not the data platform.

Consequence for pilot planning

If you're planning an AI pilot in your lab or CDMO next week, the order is:

1. Identify the two or three computation-critical steps. Where does the output need to be reproducible and audit-able? In most pharma workflows that's ICH-aligned analyses, toxicology triage, stability modelling. 2. Route those steps through deterministic tools, not the LLM. MCP servers, dedicated cheminformatics libraries, internally built Python functions with test coverage — anything beats "the LLM just computes it". 3. Let the LLM do everything else. Hypothesis generation, literature review, synthesis suggestions, result communication. There it's strong, there hallucination doesn't hurt. 4. Only then the data platform. If the pilot architecture is right, consolidating input data pays off. If the architecture is wrong, the data platform is the most expensive workaround you can buy.

What we offer concretely

CovaSyn is exactly this deterministic tool layer for pharma, biotech and chemistry. 130 functions, MCP-compatible, with audit trail out of the box. Three ways in:

Sources

CovaSyn MCP

Scientific tools in your AI workflow.

130+ functions for pharma, biotech and chemistry. Free tier instantly active.

See CovaSyn MCP →
Data quality isn't the real bottleneck. Why 55 percent of biotech AI pilots actually fail. | CovaSyn